Analysis Panacea Biotec Limited (PANACEABIO)
6/5/2024
Analysis of Panacea Biotec Limited (PANACEABIO)
Panacea Biotec Limited is showing a downward trend based on the recent data. The closing prices have been decreasing over the past few days, with the RSI indicator showing values below 50, indicating a bearish momentum.The MACD indicator is also negative, with the MACD line below the signal line, suggesting a potential for further downward movement.
The Moving Average (MA) indicator is above the current price, indicating a bearish signal.
Overall, based on the indicators and recent price movements, Panacea Biotec Limited seems to be in a bearish phase, and investors may want to exercise caution or consider short-term trading strategies.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, showing a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, showing a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
Overall, the analysts are generally optimistic about the company's future sales performance, with moderate to healthy growth expected in both the quarterly and annual periods.
Growth estimates
Based on the consensus estimates provided:- The company is expected to experience a growth rate of 7.6% in the current year and 9.7% in the next year.
- For the current quarter and the next quarter, the growth rate is estimated to be around 5.1%.
- Over the next 5 years, the company is projected to have a compound annual growth rate (CAGR) of approximately 9.7%.
- However, when looking at the past 5 years, the company has had a higher growth rate of around 20.1% per annum.
Overall, it seems that the company is expected to maintain a solid growth trajectory, with a slightly higher growth rate in the next 5 years compared to the current and previous periods.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $275
- Median: $201.43
- Average: $204.58
- Current price: $192.25
Based on these forecasts, it appears that the analysts are generally optimistic about the future price of the security, with a median and average price above the current price. However, there is a wide range between the low and high forecasts, indicating some uncertainty or differing opinions among analysts.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company had an EPS estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong cash flow with operating cash flow at $110.56 billion and levered free cash flow at $84.73 billion. The balance sheet shows a total cash of $67.15 billion, total debt of $104.59 billion, and a current ratio of 1.037. The profit margin is 26.31%, with a return on assets of 22.07% and return on equity of 147.25%. The company's fiscal year ends on September 30, 2023.
Moving on to stock statistics, the short ratio is 1.53, with 99.29 million shares shorted out of 15.31 billion float shares. The stock has a beta of 1.264, with an average 10-day trading volume of 46.86 million shares.
Valuation metrics indicate a PEG ratio of 26.32, forward P/E of 26.32, and trailing P/E of 29.59. The enterprise value is $2.95 trillion, with a market capitalization of $2.92 trillion. The stock is priced at 39.34 times its book value and 7.65 times its sales.
The stock price summary shows a 52-week low of $164.08, a high of $199.62, and a 52-week change of 6.85%. The stock's 50-day moving average is $176.26, while the 200-day moving average is $181.04.
Lastly, in terms of dividends and splits, the company has a payout ratio of 14.93% and a forward annual dividend rate of $1. The dividend yield is 0.53% on a trailing basis and 0.53% on a forward basis. The last split date was on August 31, 2020, with a 4-for-1 split. The ex-dividend date is May 10, 2024, and the dividend will be paid on May 16, 2024.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales have been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite fluctuations in other financial metrics, the revenue trend shows consistent growth.
3. The company has managed to increase its top line despite facing challenges in other areas such as operating expenses and net income.
4. The revenue growth indicates that the company's products or services are in demand and its market position is strong.
5. Investors and stakeholders can be confident in the company's ability to generate revenue and sustain growth.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets include cash, inventory, and receivables, with a significant portion in cash equivalents and short-term investments.
3. Non-current assets consist mainly of investments and advances, along with machinery, furniture, and equipment.
4. Total liabilities have also been increasing, but at a slower pace compared to assets.
5. Shareholders' equity has shown a positive trend, indicating a healthy financial position.
6. The company has been managing its short-term and long-term debts effectively.
7. Accumulated depreciation has been significant, affecting the value of non-current assets.
8. The company has been investing in leases, land, and improvements over the years.
9. There is a consistent provision for risks and charges in the liabilities section.
10. Overall, the company's financial health seems stable and improving over the years.
Cash Flow 💶
This is a cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2021.
5. Financing activities show a pattern of common stock repurchase, long-term debt issuance, and payments, with significant fluctuations in these values.
6. Investing activities reflect the company's investments in acquisitions, capital expenditures, and the sale and purchase of investments.
7. Overall, the company's financial activities show a mix of strategies to manage cash flow, invest in growth, and return value to shareholders.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average EPS estimate is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This is higher than the EPS of $1.35 from the same quarter last year.
3. Looking at the current fiscal year ending on September 30, 2024, the average EPS estimate is $6.10, with a low estimate of $5.95 and a high estimate of $6.41. This reflects growth compared to the EPS of $5.67 from the previous fiscal year.
4. For the next fiscal year ending on September 30, 2025, the average EPS estimate is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This indicates a potential increase from the EPS of $6.10 in the current fiscal year.
Overall, the analysts are forecasting growth in earnings per share for both the upcoming quarters and the full fiscal years, suggesting positive performance and potential expansion for the company.
MACD of PANACEABIO
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
